Protagenic Therapeutics Inc. (PTIX)

[point_east]

"HOW LONG UNTIL PROTAGENIC THERAPEUTICS CAN REACH DEFINED MILESTONES IN THE DEVELOPMENT OF PT00114?"

Protagenic Therapeutics is committed to advancing its biological expertise to help build a strong presence with novel, first-in-class approaches in the treatment of a variety of psychological and psychiatric diseases. We believe that understanding the biology of disease as well as the mechanism of action of a potential intervention will help facilitate more efficient and speedy clinical development while improving the probabilities of success in clinical trials. We expect our IND-enabling studies to be completed by March 2018, followed by IND submission to the FDA in the 2nd quarter of 2018. If this IND is accepted by the FDA, we anticipate being able to commence Phase I clinical trials in 2018.

http://protagenic.com/investors/investor-faq/